Life Science Intelligence

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, secure FDA clearances, appoint new board members, and much more on the road to  LSI Europe  ’25 in London (September 7–11). Acutus Medical Announced the acquisition of its AcQMap™ platform assets by EnChannel Medical to accelerate the development of next-generation non-contact mapping technologies for atrial fibrillation. The deal integrates key IP into EnChannel’s electrophysiology ecosystem, strengthening its mission to deliver precision, patient-specific AF treatment. Atmo Biosciences Received FDA 510(k) clearance for its Atmo Gas Capsule System, enabling U.S. commercialization of the company’s ingestible gas-sensing capsule for assessing gut motility. The system offers a radiation-free, clinically validated alternative for diagnosing conditions like gastroparesis and slow transit constipation. Cognito Therapeutics Completed enrollment in the pivotal HO...

The  global cardiac ablation devices market  is witnessing a significant transformation thanks to the emergence of pulsed field ablation (PFA) technology. Since its introduction in 2021, PFA has been rapidly changing the way atrial fibrillation (AFib) is treated, providing an alternative to traditional methods like radiofrequency (RF) and cryoablation. This innovative technology is now driving growth in the pulsed field ablation market, which is expected to see rapid expansion over the next few years. A New Era for Cardiac Ablation with Pulsed Field Ablation PFA uses non-thermal electroporation to selectively target myocardial cells while sparing non-cardiac tissue, offering several advantages over traditional ablation techniques. This technology significantly reduces procedure times — by 30% to 50% — resulting in better cost-efficiency and improved patient outcomes. Clinical data supports the notion that PFA may eventually match or even exceed the effectiveness of RF and cryo...

Under the direction of Founder and CEO Yosef Safi Harb, Happitech is rethinking cardiac monitoring with a next-generation smartphone-based platform, a CE-certified solution that enables long-term heart rate and rhythm tracking using only a smartphone, while also integrating with wearables and medical devices equipped with PPG sensors. By leveraging photoplethysmography (PPG) through a smartphone’s camera and flash, or any compatible sensor or wearable, Happitech delivers medical-grade insights anytime, anywhere. The platform is intended to support clinical decision-making, expand access, and reshape how atrial fibrillation (AFib) is detected and monitored today, and how other heart conditions are detected and monitored tomorrow. The Current Landscape Happitech’s foundational belief is that heart monitoring should be accessible, scalable, and effortless. Today, their CE-certified platform is already integrated into more than 50% of Dutch cardiology hospitals and supports long-term cardi...